The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from launching its aflibercept biosimilar, Amgen announced on its ...

Bayer has begun a late-stage trial of its blockbuster aflibercept eye drug to prevent blindness in premature infants. The anti-vascular endothelial growth factor (VEGF) treatment is being ...

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).

Once a subject is enrolled in the study, they receive two loading doses of aflibercept (2 mg), one ... implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor ...